Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. ONON
6. AAPL
7. RTB
8. AZN
9. SPCX
10. TRMD

Go back to Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) Delayed: 27.66 +0.02 (0.07%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.66    P/E 16.76 
Day Low $27.34    EPS $1.65 
Volume 75,587,710       

Pfizer Inc. (NYSE: PFE) Delayed: 27.66 +0.02 (0.07%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.66    P/E 16.76 
Day Low $27.34    EPS $1.65 
Volume 75,587,710       

Sangamo Biosciences, Inc. (NASDAQ: SGMO) Delayed: 0.18 --0 (-0%)
Previous Close $0.18    52 Week High $9.91 
Open $0.18    52 Week Low $3.10 
Day High $0.18    P/E N/A 
Day Low $0.18    EPS $-0.48 
Volume 1,800